Compare Dolby Laboratories, Inc. (DLB) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Sana Biotechnology Inc — how do they compare? Dolby Laboratories, Inc. trades at $49.67 (market cap $4.59B), while Sana Biotechnology Inc trades at $3.48 (market cap $994.89M). The key difference: Dolby Laboratories, Inc. is far larger — about 4.6× Sana Biotechnology Inc's market cap, and Dolby Laboratories, Inc. pays a 2.91% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DLB | SANA | |
|---|---|---|
Market Cap | $4.59B | $994.89M |
Sector | Industrials | Health |
52-Week High | $76.79 | $5.92 |
52-Week Low | $48.51 | $2.68 |
Enterprise Value | $4.04B | $969.08M |
Dividend Yield | 2.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $49.36, down 0.88% on the day, with a bearish technical outlook. The company maintains strong fundamentals, including a P/E of 19.59, a net income margin of 17.85%, and consistent earnings beats in recent quarters. Recent news highlights include its role in powering immersive audio for the FIFA World Cup 2026 coverage and recognition as a top supplier by General Motors.
The stock presents a value opportunity given its discount to the analyst consensus price target of $87.50, but faces near-term headwinds from bearish technical signals and cyclical end-market exposure. Upside potential hinges on continued licensing growth and execution, while risks include market sentiment and competitive pressures.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
